

May 28, 2021

News Release

Company: Olympus Corporation
Yasuo Takeuchi, Director, Representative Executive Officer, President and CEO
(Code: 7733, First Section, Tokyo Stock Exchange)
Contact: Takaaki Sakurai, Vice President, Investor Relations
TEL: +81-3-3340-2111

**(Progress of disclosure matters) Notice Regarding Completion of Acquisition of
Israeli medical device company Medi-Tate Ltd. (new subsidiary)**

Olympus Corporation ("Olympus") hereby announces that we exercised our call option and completed the acquisition of all outstanding shares (excluding shares already held by Olympus) of Medi-Tate Ltd., registered in Israel, a medical device company, through Olympus Winter & Ibe GmbH (headquartered in Germany), our consolidated subsidiary, on May 27, 2021 (Central European Time). The acquisition was originally announced in the timely disclosures "Notice Regarding start of the process to acquire Israeli medical device company Medi-Tate Ltd. (new subsidiary) pursuant to its call option rights" dated February 26, 2021 and "(Change of Disclosure Matters) Notice Regarding start of the process to acquire Israeli medical device company Medi-Tate Ltd. (new subsidiary) pursuant to its call option rights" dated April 30, 2021.

1. Overview of the subsidiary to be acquired

(1) Name	Medi-Tate Ltd.
(2) Address	17 Hauman st., Hadera, Israel
(3) Title and name of representative	CEO Ido Kilemnik
(4) Description of business	R&D and manufacturing of medical devices
(5) Capital Amount (Note 1)	JPY 1 million (at the end of April 2021)
(6) Date of incorporation	26 February, 2007
(7) Major shareholders and shareholding ratios (Note 2)	Olympus Winter & Ibe GmbH, 18.46% (Note 3) Ido Kilemnik, 14.23% Xenia Venture Limited, 14.10% P&T International Group, 8.02%

(Note 1) Calculated at the exchange rate of JPY 108.93 per USD (exchange rate as of the end of April 2021).

(Note 2) The shareholding ratio is calculated based on the total number of shares outstanding before dilution.

(Note 3) The shares were transferred from Olympus to Olympus Winter & Ibe GmbH on March 16, 2021.

2. Date of acquisition

May 27, 2021 (Central European Time)

3. Acquisition amount

Amount invested (Note 1)	Approx. USD 20 million (Approx. JPY 2.2 billion (Note 2))
Purchase price of stock	Approx. USD 200 million (Approx. JPY 21.8 billion (Note 2))
Conditional payments (Note 3)	Up to USD 40 million (JPY 4.4 billion (Note 2))
Total	Approx. USD 260 million (Approx. JPY 28.3 billion (Note 2))

(Note 1) Includes (1) underwriting preferred E shares, (2) the right for a call option (3) the right to distribute Medi-Tate's products. Since we have not agreed on the breakdown of (1) to (3), the total amount is shown.

(Note 2) Calculated at the exchange rate of JPY 108.93 per USD (exchange rate as of the end of April 2021).

(Note 3) The conditional payments have not been finalized as of the date hereof and are contingent on achievement of an earn-out target by a certain date.

4. Future Outlook

Olympus does not believe that there will be a material impact on the financial results for the year ending March 31, 2022. Olympus will promptly provide notice as soon as additional items to be disclosed have arisen.